Merck Demands Gilead Pay $3B-Plus in Hep C Royalties

Mar 08, 2016

Bloomberg

A compound in Gilead’s Sovaldi and Harvoni was found by a judge last month to have infringed Merck’s patents

Gilead Sciences Inc., which manufactures a drug to cure hepatitis C, is fighting a demand by Merck & Co. for more than $3 billion in a patent dispute, according to a Bloomberg report.

A compound in Gilead’s blockbuster drugs Sovaldi and Harvoni was found by a judge recently to have infringed Merck’s patents, the article said. The next step is for a jury to decide whether those patents are still valid, and if so, how much Gilead has to pay Merck in royalties. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments